ArticleNPJ vaccines2019
An autophagy-inducing and TLR-2 activating BCG vaccine induces a robust protection against tuberculosis in mice.
Open access · goldAbstract read
In one paragraph
Article in NPJ vaccines, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- The Role of Toll-like Receptor 2 Polymorphisms in Susceptibility to and Severity of Tuberculosis: A Systematic Review.Pathogens (Basel, Switzerland) · 2026Pooled it
- Antigen 85B ofVaccines · 2026Review
- Sirtuin2 blockade inhibits replication of human immunodeficiency virus-1 and Mycobacterium tuberculosis in macrophages and humanized mice.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Construction and characterization of novelInfection and immunity · 2026Article
- A multi species autophagy-inducing nano-vaccine platform: uncovering immunoenhancement properties of PCV2 cap nanoparticles.Journal of nanobiotechnology · 2026Article
- BCG overexpressing Ag85B reprograms host immune response through coordinated transcriptional networks.Frontiers in immunology · 2026Article
- The TRIM-cancer paradox: BCG as a programmable vaccine platform and a mechanistic probe for rational immunotherapy design.Frontiers in immunology · 2026Review
- Targeting pattern recognition receptors for cancer therapy: Mechanisms and strategies.Acta pharmaceutica Sinica. B · 2025Review
- A bovine adenoviral-vector-based universal influenza vaccine confers protection against influenza A and B viruses in mice and ferrets.Molecular therapy. Nucleic acids · 2025Article
- Advances in Targeted Autophagy Modulation Strategies to Treat Cancer and Associated Treatment-Induced Cardiotoxicity.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Article
- Impact of Mygalin on Inflammatory Response Induced by Toll-like Receptor 2 Agonists and IFN-γ Activation.International journal of molecular sciences · 2024Article
- STING agonists as promising vaccine adjuvants to boost immunogenicity against SARS-related coronavirus derived infection: possible role of autophagy.Cell communication and signaling : CCS · 2024Review
- Live Attenuated Vaccines against Tuberculosis: Targeting the Disruption of Genes Encoding the Secretory Proteins of Mycobacteria.Vaccines · 2024Review
- Advancements in Vaccine Strategies for Chronic Liver Disease Patients: Navigating Post-COVID Challenges and Opportunities.Vaccines · 2024Review
- A viral vaccine design harnessing prior BCG immunization confers protection against Ebola virus.Frontiers in immunology · 2024Article
- Article
- Next generation self-replicating RNA vectors for vaccines and immunotherapies.Cancer gene therapy · 2023Review
- Article
- Reversing BCG-mediated autophagy inhibition and mycobacterial survival to improve vaccine efficacy.BMC immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 7 institutions in 1 country.
Arshad Khan *1Department of Pathology and Laboratory Medicine, University of Texas Health Sciences Center, Houston, TX USA.ORCID 0000-0003-3655-2854
Pearl Bakhru *1Department of Pathology and Laboratory Medicine, University of Texas Health Sciences Center, Houston, TX USA.
Sankaralingam Saikolappan2Molecular and Translational Medicine, Paul L. Foster School of Medicine Texas Tech University Health Sciences Center, El Paso, TX USA.
Kishore Das2Molecular and Translational Medicine, Paul L. Foster School of Medicine Texas Tech University Health Sciences Center, El Paso, TX USA.
Emily Soudani1Department of Pathology and Laboratory Medicine, University of Texas Health Sciences Center, Houston, TX USA.
Christopher R Singh1Department of Pathology and Laboratory Medicine, University of Texas Health Sciences Center, Houston, TX USA.
Jaymie L Estrella1Department of Pathology and Laboratory Medicine, University of Texas Health Sciences Center, Houston, TX USA.
Dekai Zhang3Institute of Biosciences and Technology, Texas A&M University Health Science Center, Houston, TX USA.
Chandrashekhar Pasare4Division of Immunobiology, Center for Inflammation and Tolerance, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229 USA.ORCID 0000-0002-8142-2488
Yue Ma5Department of Biological Sciences and Border Biomedical Research Center, University of Texas at El Paso, Houston, TX USA.
Jianjun Sun5Department of Biological Sciences and Border Biomedical Research Center, University of Texas at El Paso, Houston, TX USA.
Jin Wang6Methodist Hospital Research Institute, Houston, TX USA.
Robert L Hunter1Department of Pathology and Laboratory Medicine, University of Texas Health Sciences Center, Houston, TX USA.
N Tony Eissa7Baylor College of Medicine, Houston, TX USA.
Subramanian Dhandayuthapani *2Molecular and Translational Medicine, Paul L. Foster School of Medicine Texas Tech University Health Sciences Center, El Paso, TX USA.
Chinnaswamy Jagannath *1Department of Pathology and Laboratory Medicine, University of Texas Health Sciences Center, Houston, TX USA.
The University of Texas Health Science Center at Houston · USTexas Tech University · USHouston Methodist · USThe University of Texas at El Paso · USBaylor College of Medicine · USCincinnati Children's Hospital Medical Center · USTexas A&M Health Science Center · US
Funding
Virology CoreP30AI036211 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI BUTEL, JANET S · 1994 to 2015
$21.7MChracteristics of An M. Tuberculosis Derived VaccineR01AI049534 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI JAGANNATH, CHINNASWAMY · 2002 to 2011
$3.4MMolecular Basis of Infectious Diseases Training GrantT32AI055449 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI LORENZ, MICHAEL C · 2005 to 2025
$2.6MMechanisms of Mycobacterial Antigen ProcessingR01AI078420 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI JAGANNATH, CHINNASWAMY · 2009 to 2013
$2.2MiNOS Aggresome as a Prototype of a Physiologic AggresomeR01HL080205 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI EISSA, N. TONY · 2006 to 2010
$1.8MNHLBI NIH HHS R01 HL080205NIAID NIH HHS P30 AI036211NIAID NIH HHS R01 AI049534NIAID NIH HHS R01 AI078420NIAID NIH HHS T32 AI055449
Abstract
PubMed holds no abstract for this paper.
Indexed as
Live attenuated vaccinesVaccines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.